Health IT Analytics February 7, 2018
Jennifer Bresnick

The FDA draft guidance on clinical decision support tools does not adequately account for the rapid growth of machine learning, AMIA says.

The FDA’s recent guidance on classifying and regulating clinical decision support (CDS) systems is currently too ambiguous for developers to effectively follow, contends the the American Medical Informatics Association (AMIA) in a response to the draft framework.

The FDA guidance, published in accordance with provisions in the 21st Century Cures Act, is intended to help developers and vendors understand which CDS products may require more extensive review by the regulatory agency.

But the guidance is not as clear as it could be when it comes to the fastest-growing category of clinical decision support tools: those that are powered...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Cures Act, FDA
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article